Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
4.73 | -1.87% | -0.09 |
ALNA closed down 1.87 percent on Thursday, July 18, 2019, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: Jul 25
*** please verify all earnings dates ***| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical ALNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 50 DMA Support | Bullish | -1.87% | |
| Narrow Range Bar | Range Contraction | -1.87% | |
| Narrow Range Bar | Range Contraction | -3.47% | |
| NR7 | Range Contraction | -3.47% | |
| NR7-2 | Range Contraction | -3.47% | |
| 50 DMA Support | Bullish | -4.83% | |
| NR7 | Range Contraction | -4.83% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 07/25/2019
- Sector: Healthcare
- Industry: Biotechnology
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ALNA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.38 |
| 52 Week Low | 3.92 |
| Average Volume | 163,476 |
| 200-Day Moving Average | 6.9667 |
| 50-Day Moving Average | 4.7912 |
| 20-Day Moving Average | 4.7365 |
| 10-Day Moving Average | 4.932 |
| Average True Range | 0.4163 |
| ADX | 21.52 |
| +DI | 25.3552 |
| -DI | 20.4541 |
| Chandelier Exit (Long, 3 ATRs ) | 4.4911 |
| Chandelier Exit (Short, 3 ATRs ) | 5.2489 |
| Upper Bollinger Band | 5.3534 |
| Lower Bollinger Band | 4.1196 |
| Percent B (%b) | 0.49 |
| BandWidth | 26.04877 |
| MACD Line | 0.0306 |
| MACD Signal Line | 0.0096 |
| MACD Histogram | 0.021 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.27 | ||||
| Resistance 3 (R3) | 5.25 | 5.06 | 5.18 | ||
| Resistance 2 (R2) | 5.06 | 4.92 | 5.07 | 5.15 | |
| Resistance 1 (R1) | 4.89 | 4.83 | 4.80 | 4.91 | 5.12 |
| Pivot Point | 4.70 | 4.70 | 4.65 | 4.71 | 4.70 |
| Support 1 (S1) | 4.53 | 4.56 | 4.44 | 4.55 | 4.34 |
| Support 2 (S2) | 4.34 | 4.47 | 4.35 | 4.31 | |
| Support 3 (S3) | 4.17 | 4.34 | 4.28 | ||
| Support 4 (S4) | 4.19 |
